Hoechst Marion Roussel Nilandron launched as "affordable" prostate cancer treatment.
Executive Summary
HOECHST MARION ROUSSEL NILANDRON LAUNCHED AT 20% AWP DISCOUNT to Eulexin (flutamide) in the prostate cancer market. Nilandron (nilutamide) costs $233.53 per month for 90 tablets AWP. Schering's antiandrogen product Eulexin costs $291.96 per month AWP. Nilandron also costs less than Zeneca's Casodex (bicalutamide) with an AWP of $307.50 per month. Shipment of the Hoechst product has begun; FDA approved the drug on Sept. 19.